Table 3.
Age at Dx (y) | MRD_EOI | IGH_V(D)J | IKZF1 | UPN | Fusion | Response EOI | Therapy |
---|---|---|---|---|---|---|---|
17 | 9.00E-03 | – | del 1–8 | 37 | BCR-ABL1 | yes | Tx |
17.5 | 9.00E-02 | – | del 4–7 | 21 | CRLF2-IGH | LateResp | Tx |
11 | 9.00E-02 | – | del 2–8 | 1 | DUX4-IGH | LateResp | Tx |
16 | 2.00E-02 | – | wt | 10 | DUX4-IGH | pesistent MRD | Tx |
5 | 2.00E-03 | – | del 4–7 | 8 | DUX4-IGH | Yes | Remission |
10 | 7.00E-02 | – | wt | 61 | EBF-PDGFRB | LateResp | /COALLa |
7.5 | 4.00E-01 | – | del 2–7 | 12 | EPOR-IGH | LateResp | TRM |
13 | 2.00E-01 | – | del 4–8 | 16 | EPOR-IGH | LateResp | Tx |
17.5 | 9.00E-02 | – | del 2–3 | 13 | EPOR-IGH | LateResp | Tx |
16 | 5.00E-02 | – | del 2–8 | 69 | FOXP1-ABL1 | LateResp | Tx |
12 | 2.00E-02 | – | wt | 72 | n.d. | LateResp | Rel/Tx 2.rem |
n.d. not detectable, Rel relapse, Rem remission, Tx Hematopoietic Stem Cell Transplantation
EOI end of induction therapy, TRM treatment related mortality
aoff protocol treatment intensification